For the quarter ending 2025-09-30, IMNN has $8,987,733 in assets. $4,906,009 in debts. $5,250,929 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 5,250,929 | 4,728,776 | ||
| Advances and deposits on clinical programs and other current assets | 2,006,756 | 2,162,469 | ||
| Total current assets | 7,257,685 | 6,891,245 | ||
| Property and equipment (at cost, less accumulated depreciation and amortization) | 601,425 | 676,565 | ||
| Operating lease right-of-use assets, net | 1,078,623 | 1,170,517 | ||
| Deposits and other assets | 50,000 | 50,000 | ||
| Total other assets | 1,128,623 | 1,220,517 | ||
| Total assets | 8,987,733 | 8,788,327 | ||
| Accounts payable trade | 1,126,826 | 1,735,568 | ||
| Other accrued liabilities | 2,676,951 | 3,199,502 | ||
| Operating lease liabilities - current portion | 394,135 | 382,217 | ||
| Total current liabilities | 4,197,912 | 5,317,287 | ||
| Operating lease liabilities - non-current portion | 708,097 | 811,190 | ||
| Total liabilities | 4,906,009 | 6,128,477 | ||
| Common stock - 0.01 par value (350,000,000 and 112,500,000 shares authorized at september 30, 2025 and december 31, 2024, respectively) 2,896,275 and 966,714 shares issued at september 30, 2025 and december 31, 2024, respectively and 2,896,273 and 966,712 shares outstanding at september 30, 2025 and december 31, 2024, respectively) | 28,963 | 17,175 | ||
| Additional paid-in capital | 421,213,171 | 416,373,961 | ||
| Accumulated deficit | -417,075,222 | -413,646,098 | ||
| Total stockholders equity before treasury stock | 4,166,912 | 2,745,038 | ||
| Treasury stock, at cost (2 shares at september 30, 2025 and december 31, 2024) | 85,188 | 85,188 | ||
| Total stockholders equity | 4,081,724 | 2,659,850 | ||
| Total liabilities and stockholders equity | 8,987,733 | 8,788,327 | ||
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)